宝莱特(300246) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 344,565,792.16, representing an increase of 18.09% compared to CNY 291,794,237.98 in the same period last year[5] - Net profit attributable to shareholders reached CNY 27,162,153.53, a significant increase of 94.75% from CNY 13,947,291.98 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 23,081,480.62, up 80.71% from CNY 12,772,332.15 in the previous year[5] - Basic earnings per share rose to CNY 0.1545, an increase of 83.06% compared to CNY 0.0844 in the same quarter last year[5] - Operating profit surged by 117.53% to ¥36,002,392.50 driven by increased product sales revenue and gross margin growth[10] - Net profit increased by 97.80% to ¥28,305,836.21 attributed to higher product sales revenue and gross margin[11] - The company reported a total comprehensive income of ¥28,710,677.12, compared to ¥13,520,521.78 in the same quarter last year[21] Assets and Liabilities - The company's total assets increased by 6.00% to CNY 2,585,169,605.44 from CNY 2,438,861,738.92 at the end of the previous year[5] - As of March 31, 2023, the total assets of Guangdong Baolait Medical Technology Co., Ltd. amounted to CNY 2,585,169,605.44, an increase from CNY 2,438,861,738.92 at the beginning of the year, reflecting a growth of approximately 6.0%[17] - Total current liabilities increased to CNY 673,808,834.57 from CNY 603,389,790.05, marking an increase of about 11.6%[18] - The company's total equity as of March 31, 2023, was CNY 1,536,095,250.43, up from CNY 1,502,442,989.80, showing a growth of about 2.2%[18] - The total liabilities of the company increased to CNY 1,049,074,355.01 from CNY 936,418,749.12, reflecting an increase of approximately 12.0%[18] Cash Flow - The net cash flow from operating activities was negative at CNY -63,981,560.58, a decline of 1,075.54% from CNY 6,558,556.06 in the previous year[5] - Cash flow from operating activities showed a net outflow of ¥63,981,560.58, compared to a net inflow of ¥6,558,556.06 in Q1 2022[23] - The net cash flow from financing activities was ¥130,778,416.32, a decrease from ¥514,743,668.08 in the previous year[24] - The total cash and cash equivalents at the end of the period amounted to ¥434,543,141.97, down from ¥740,565,884.82 year-over-year[24] - The net increase in cash and cash equivalents for the quarter was ¥32,130,753.01, significantly lower than ¥473,952,206.85 in the previous year[24] Research and Development - Research and development expenses increased by 33.29% to CNY 24,786,031.00 from CNY 18,595,887.26 year-on-year[9] - Research and development expenses grew by 33.29% to ¥24,786,031.00 reflecting increased investment in R&D[10] Investments and Income - The company reported a significant increase in investment income, which rose to CNY 2,663,044.36, compared to a loss of CNY -69,780.89 in the previous year, marking a 3,916.29% change[9] - Total revenue from government subsidies rose by 369.07% to ¥12,644,802.89 during the reporting period[10] - The company recorded a significant increase in other income to ¥12,644,802.89, compared to ¥2,695,742.22 in Q1 2022[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,305[13] - Earnings per share increased by 83.06% to ¥0.1545 due to the growth in net profit attributable to shareholders[11] - The total equity attributable to shareholders of the parent company increased to ¥1,445,011,388.04, compared to ¥1,416,280,945.57 in the previous year[19] Inventory and Receivables - Accounts receivable decreased by 44.84% to ¥3,869,844.66 due to the maturity of bank acceptance bills during the reporting period[10] - Prepayments increased by 33.89% to ¥41,889,070.78 as the company increased advance payments for sales inventory[10] - Inventory rose by 52.78% to ¥306,438,713.62 due to increased procurement for sales inventory[10] Borrowings - The company received cash from bank loans amounting to ¥165,300,000.00, a 1036.07% increase compared to the previous period[11] - Short-term borrowings rose to CNY 209,996,000.00, compared to CNY 132,640,000.00 at the beginning of the year, reflecting an increase of approximately 58.2%[18] - The long-term borrowings increased to CNY 107,520,000.00 from CNY 68,520,000.00, representing a rise of approximately 56.9%[18] - The company’s cash received from borrowings was ¥165,300,000.00, compared to ¥14,550,125.00 in the previous year[24] Audit Information - The company did not conduct an audit for the first quarter report[25]